Electromed (NYSE American: ELMD) reported fiscal Q4 2026 net revenue of $19.4 million, up 11.6% year over year, while diluted EPS rose to $0.39 from $0.25. Direct homecare growth and slower SG&A growth relative to revenue lifted operating margin to 19.7%, although full-year operating cash flow declined as receivables increased.

Core Earnings Data

For the three months ended June 30, 2026, revenue growth carried through to higher gross and operating profit. Gross margin increased by 40 basis points, supported by higher net revenue per device, while operating margin expanded by 220 basis points.

Net income grew considerably faster than operating income, partly because quarterly income tax expense declined to $0.56 million from $0.97 million.

Business and Segment Performance

Direct homecare remained the main growth engine. Quarterly homecare revenue increased 15.2% to $17.7 million from $15.4 million, reflecting more direct sales representatives, higher representative productivity, and greater net revenue per approval.

The full-year results show a similar pattern. Fiscal 2026 homecare revenue rose 16.3% to $66.6 million, compared with 6.7% growth in non-homecare revenue to $7.2 million. The company averaged 58 homecare field sales representatives, and revenue per weighted-average direct representative reached $1.145 million, above Electromed’s $1.0 million to $1.1 million target range for the year.

Non-homecare growth was primarily attributed to higher distributor and hospital revenue, but this business remained much smaller than direct homecare.

Operating Leverage and Lower Tax Expense Drove EPS Growth

Electromed expanded its sales, marketing, support, and reimbursement teams to process more patient referrals. That increased salaries and incentive compensation, but quarterly SG&A growth of 8.3% remained below revenue growth of 11.6%. This difference helped operating income rise 25.8% and operating margin reach 19.7%.

The increase in net income was also supported by a lower tax burden. Pretax income rose to $3.96 million from $3.18 million, while income tax expense fell to $0.56 million from $0.97 million. Based on the reported figures, the implied quarterly effective tax rate was approximately 14%, compared with approximately 31% a year earlier. Investors should therefore distinguish the underlying operating improvement from the additional benefit of lower tax expense.

Full-Year Cash Flow and Balance Sheet

Cash conversion did not rise with earnings during fiscal 2026. Full-year net income increased to $11.3 million from $7.5 million, but operating cash flow declined to $9.7 million from $11.4 million.

Receivables were the largest working-capital drag shown in the cash flow statement. Accounts receivable used $5.1 million of cash during fiscal 2026, compared with $1.3 million in the prior year, and the ending balance increased to $29.8 million from $24.7 million.

Despite the decline in operating cash flow, Electromed ended June 2026 with $20.5 million in cash, no debt, and working capital of $45.1 million. Cash increased by $5.2 million during the year after the company spent $3.9 million repurchasing common shares.

Management Commentary

President and CEO Jim Cunniff said fiscal Q4 represented Electromed’s 15th consecutive quarter of year-over-year revenue and profit growth. Management linked its longer-term growth plans to continued investment in the sales force, operating systems, and bronchiectasis market development initiatives.

The company estimates that approximately 800,000 diagnosed bronchiectasis patients could benefit from SmartVest therapy. That figure describes the potential patient population identified by management rather than current customers or realized revenue.

Recent Insider Transactions

The supplied six-month summary reported three insider purchases totaling 59,301 shares and three sales totaling 61,501 shares, resulting in a net sale of 2,200 shares, or 0.20% of total insider shares held. The latest reported records included sales paired with derivative exercises, as well as four director stock awards; these transactions are presented without inferring insider sentiment.

Risks Investors Should Monitor

• Dependence on direct homecare: Direct homecare accounted for approximately 91% of quarterly revenue. Overall growth is therefore sensitive to sales representative productivity, patient referrals, payer approvals, and reimbursement levels.
• Receivables and cash conversion: The increase in accounts receivable contributed to lower full-year operating cash flow even as net income rose. Continued receivables growth could limit the amount of reported profit converted into cash.
• Earnings comparability: Lower tax expense helped net income and EPS grow much faster than operating income in Q4. The quarter’s bottom-line growth rate was therefore not solely the result of operating performance.
• Expense execution: Electromed is investing in sales, marketing, support, and reimbursement personnel. Maintaining operating leverage depends on revenue and referral growth continuing to outpace the associated compensation costs.

Summary

Electromed’s fiscal Q4 2026 results reflected continued homecare expansion, higher revenue per device, and improved operating leverage. The main items to monitor are whether sales-force productivity can sustain homecare growth, whether receivables stabilize enough to improve cash conversion, and how much of the quarterly EPS growth persists without the benefit of unusually lower tax expense.

Find out more